Last updated on April 2020

Mild Alzheimer’s Disease Study in patients with Glucose Intolerance (T2DM)

Brief description of study

The Memory Health Center at Summit Research Network, is enrolling participants in a new mild Alzheimer’s clinical trial. This trial will evaluate the safety and effectiveness of the study medication, azeligaron in the treatment of mild Alzheimer’s disease in patients who also have glucose intolerance or Type 2 Diabetes: those with HGbA1c of 6.5% to 9.5%).

Study participation will last about eleven months. Following an approximate 60 day screening period, qualified participants will be randomly assigned to the study medication, azeligaron, or a placebo (an inactive substance). During the treatment period, the participants will visit the research center 2 times over a 6 month period. All participants will come back 3 months after the final study visit for a follow-up visit.


Clinical Study Identifier: TX228542

Find a site near you

Start Over

Summit Research Network, Inc.

2701 NW Vaughn Street, Suite 350 Portland, OR USA
  Connect »